Professional
Added to YB: 2024-08-21
Pitch date: 2024-06-30
RGEN [bullish]
Repligen Corporation
+25.53%
current return
Author Info
No bio for this author
Company Info
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally.
Market Cap
$8.6B
Pitch Price
$125.94
Price Target
N/A
Dividend
N/A
EV/EBITDA
51.33
P/E
6.0K
EV/Sales
12.03
Sector
Life Sciences Tools and Services
Category
turnaround
Polen U.S. SMID Company Growth New Position: Repligen Corporation
RGEN: Leading bioprocessing tech provider. Strategic acquisitions in filtration & analytics. $12B global market. Pandemic sales decline created opportunity. Well-positioned for market share gains in biopharma/CDMO. Uniquely positioned with technical leadership in complex bioprocessing workflow for biologic drug development & manufacturing.
Read full article (1 min)